B-cell prolymphocytic leukaemia with a t(4;14) FGFR3/IGH translocation: response to ibrutinib

Pathology. 2020 Jun;52(4):491-492. doi: 10.1016/j.pathol.2020.03.005. Epub 2020 Apr 27.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Adenine / analogs & derivatives*
  • Adenine / pharmacology
  • Adenine / therapeutic use
  • Aged
  • Antineoplastic Agents / pharmacology
  • Antineoplastic Agents / therapeutic use
  • Humans
  • Leukemia, Prolymphocytic, B-Cell / diagnosis
  • Leukemia, Prolymphocytic, B-Cell / drug therapy
  • Leukemia, Prolymphocytic, B-Cell / pathology*
  • Male
  • Piperidines / pharmacology
  • Piperidines / therapeutic use*
  • Receptor, Fibroblast Growth Factor, Type 3 / drug effects
  • Receptor, Fibroblast Growth Factor, Type 3 / metabolism*

Substances

  • Antineoplastic Agents
  • Piperidines
  • ibrutinib
  • FGFR3 protein, human
  • Receptor, Fibroblast Growth Factor, Type 3
  • Adenine